-
Dr. Sizhou Feng’s Team Breakthroughs: Identifying Infection Risk Factors and Optimizing Differential Diagnosis Strategies for Hematological Patients
1. Clinical Characteristics and Risk Factors for 28-Day Mortality in Adult Hematological Patients with Stenotrophomonas maltophilia Bloodstream Infections Stenotrophomonas maltophilia (SM) is a Gram-negative, non-fermentative bacterium known for its ability…
-
ASH 2024 | Dr. Hu Zhou: Exploring the Efficacy and Safety of a Novel SYK Inhibitor in Patients with Relapsed/Refractory ITP
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, drawing global experts and scholars to discuss the latest advancements in hematology. In recent years, increasing insights into the pathogenesis of immune thrombocytopenia (ITP) have paved the way for innovative treatment strategies, among which SYK…
-
ASH 2024 | Dr. Qingqing Cai on Innovations in Immunotherapy for Relapsed/Refractory Lymphoma
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA, bringing together global experts and scholars in hematology to discuss the latest research developments. At this year’s conference, Dr. Qingqing Cai’s team from Sun Yat-sen University Cancer Center presented two research posters (P3047, P4450),…
-
ASH 2024 | Dr. Wei Xu: Redefining CNS Involvement Evaluation and Prophylactic Strategies with CSF-ctDNA Testing
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this prestigious event, Dr. Wei Xu’s team from The First Affiliated Hospital of Nanjing Medical University presented their groundbreaking research titled Clinical…
-
ASH 2024 | Dr. Yang Liang: New Insights and Future Perspectives on Clonal Hematopoiesis
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, USA, bringing together global experts and scholars to discuss cutting-edge advancements in hematology. At this year’s conference, Dr. Yang Liang’s team from Sun Yat-sen University Cancer Center presented groundbreaking research on the mechanisms of clonal hematopoiesis…
-
ASH 2024 | Dr. Haiwen Huang: Insights into New Strategies for Non-Hodgkin Lymphoma (NHL)—CMOP±R Regimen, Combined Therapies, and Transplant Options
From December 7–10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego, USA, gathering leading global experts to discuss the latest advancements in hematology. At this year’s conference, Dr. Haiwen Huang’s team from The First Affiliated Hospital of Soochow University presented three impactful studies through poster sessions…
-
SABCS 2024 | Dr. Biyun Wang: Real-World Comparison of CDK4/6 Inhibitor + Endocrine Therapy vs. Chemotherapy for First-Line HR+/HER2- MBC Treatment
In the treatment landscape of HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become a widely used first-line treatment. However, patients with symptomatic visceral metastases often opt for chemotherapy (CT). While some prospective studies suggest that CDK4/6i + ET may yield better outcomes even in patients with visceral metastases,…
-
SABCS 2024 | Dr. Biyun Wang: Latest Clinical Trial Results of GQ1005 in HER2-Positive Metastatic Breast Cancer Patients
The 47th San Antonio Breast Cancer Symposium (SABCS) is in full swing in San Antonio, USA, showcasing cutting-edge research from around the world. On December 12 (Central Time), during the “Poster Spotlight – Session 8: Novel HER2 Therapeutics”, Dr. Biyun Wang and her team from Fudan University Shanghai Cancer Center presented their groundbreaking findings on…
Connecting Medical Expertise through Media